Can you take Flibanserin with Repotrectinib?
1 drug interaction and 12 additional warnings found for the following 2 drugs:
- flibanserin
- repotrectinib
Drug interactions
Moderate drug interactions
Moderate:
flibanserin repotrectinib
Applies to: flibanserin and repotrectinib
Flibanserin may increase the blood levels of repotrectinib.
This may increase the risk and/or severity of side effects such as dizziness, tiredness, muscle pain, nausea, change in your sense of taste, feeling numbness or tingling in your arms or legs, constipation, trouble with balance, shortness of breath, problems with thinking such as forgetfulness or confusion and hallucinations, as well as more serious side effects such severe or life-threatening inflammation of the lungs and liver injury.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
flibanserin Food/Lifestyle
Applies to: flibanserin
Do not use alcohol too close to the dosing time of flibanserin. Doing so can cause excessive drowsiness and decreases in blood pressure, which may lead to:
- dizziness
- lightheadedness
- fainting
- accidental injury
What to do: Take flibanserin at bedtime to minimize the risk of these effects. It is recommended that you stop drinking alcohol at least two hours before taking flibanserin; otherwise, you should just skip the flibanserin dose that evening. Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.
Because grapefruit juice can significantly increase the blood levels of flibanserin, you should also avoid the consumption of grapefruit and grapefruit juice during treatment.
Talk to your healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Major:
repotrectinib Food/Lifestyle
Applies to: repotrectinib
Consumption of grapefruit, grapefruit juice, supplements that contain grapefruit, and Seville oranges should be avoided during treatment with repotrectinib as they may increase the blood levels of repotrectinib.
This may increase the risk and/or severity of side effects such as:
- dizziness
- tiredness
- muscle pain
- nausea
- change in your sense of taste
- feeling numbness or tingling in your arms or legs
- constipation
- trouble with balance
- shortness of breath
- problems with thinking such as forgetfulness or confusion and hallucinations
- as well as more serious side effects such as severe or life-threatening inflammation of the lungs and liver injury
Talk to your doctor if you have any questions or concerns. Your doctor may be able to provide alternatives that do not interact.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
10 potential interactions Applies to: 9 conditions, including Asthma, COPD, Hypotension, Syncope, and Liver Disease.
Alcoholism
Major:
flibanserin
Flibanserin has a major potential interaction with Alcoholism.
The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope. It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.
Asthma
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Asthma.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
COPD
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with COPD.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
Hypotension
Major:
flibanserin
Flibanserin has a major potential interaction with Hypotension.
The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.
Interstitial Lung Disease
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Interstitial Lung Disease.
Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.
Liver Disease
Major:
flibanserin
Flibanserin has a major potential interaction with Liver Disease.
Flibanserin may accumulate in patients with hepatic impairment. Therapy with flibanserin is contraindicated in patients with compromised hepatic function.
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Liver Disease.
Repotrectinib can cause hepatotoxicity; this may be considered in patients with liver problems. The effect of moderate or severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal and any AST) on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with moderate or severe liver dysfunction.
Neurological Disorders
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Neurological Disorders.
Repotrectinib can cause central nervous system (CNS) adverse reactions including dizziness, ataxia, cognitive disorders, mood disorders, and sleep disorders. This may be considered in patients with neurological problems. Patients should be advised to contact their health care provider for new/worsening CNS symptoms.
Renal Dysfunction
Moderate:
repotrectinib
Repotrectinib has a moderate potential interaction with Renal Dysfunction.
The effect of severe renal dysfunction, kidney failure (estimated GFR less than 30 mL/min), or dialysis on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with severe renal dysfunction or kidney failure or in patients on dialysis.
Syncope
Major:
flibanserin
Flibanserin has a major potential interaction with Syncope.
The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.
Report options
More resources
flibanserin
A total of 517 drugs are known to interact with flibanserin.
- Flibanserin is in the drug class miscellaneous central nervous system agents.
- Flibanserin is used to treat Hypoactive Sexual Desire Disorder.
repotrectinib
A total of 701 drugs are known to interact with repotrectinib.
- Repotrectinib is in the drug class multikinase inhibitors.
- Repotrectinib is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.